Methods Of Treating Asthma .

Wyeth
Abandoned App No 2029/KOLNP/2006 Chemical

Patent information

IP India · live record
Application number
2029/KOLNP/2006
Filing date
19 July 2006
Status
Abandoned
Publication number
20/2007
Publication type
INA
Invention field
Chemical

Abstract

Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the producfion of a PKC-Θ protein, as well as for agents that inhibit the kinase activity of a PKC-Θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC -Θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-Θ protein or the kinase activity of a PKC-Θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-Θ is also disclosed.

Applicants

1
U.S.A.
WYETH FIVE GERALD FARMS, MADISON, NJ 07940

Inventors

5
U.S.A.
CHAUDHARY, DIVYA27 JENKINS ROAD, ANDIVER, MA 01810
U.S.A.
KASAIAN, MARION18 CONCORD STREET, #1, CHARLESTOWN, MA 02129,
U.S.A.
WILLIAMS, CARA11, OBSERVATORY ROAD, METHUEN, MA 01844,
U.S.A.
MARUSIC, SUZANA70 DIVIDENCE ROAD, READING, MA 01867
U.S.A.
CZERWINSKI, ROBERT, M160 OLD WESTBOARDE ROAD, NORTH GRAFTO9N, MA 01536

Specification

Show full textCollapse

Methods for agents useful for treating asthma are disclosed. The methods include screening for agents that inhibit the producfion of a PKC-Θ protein, as well as for agents that inhibit the kinase activity of a PKC-Θ protein, or a functional fragment thereof, wherein such agents are useful for treating asthma. The methods also include screening for agents that inhibit the production of a reporter gene product encoded by a nucleic acid sequence operably linked to a PKC -Θ promoter. Also disclosed are methods of treating asthma that include administering an agent that inhibits the production of a functional PKC-Θ protein or the kinase activity of a PKC-Θ protein or a functional fragment thereof. An isolated mast cell lacking expression of endogenous PKC-Θ is also disclosed.

Documents

Sign in to open
Application documents
1 02029-kolnp-2006-form-3-1.1.pdf 07 Oct 2011
2 02029-kolnp-2006-form-18.pdf 07 Oct 2011
3 02029-kolnp-2006-correspondence-1.2.pdf 07 Oct 2011
4 02029-kolnp-2006-correspondence-1.1.pdf 07 Oct 2011
5 02029-kolnp-2006 priority document.pdf 07 Oct 2011
6 02029-kolnp-2006 pct form.pdf 07 Oct 2011
7 02029-kolnp-2006 others.pdf 07 Oct 2011
8 02029-kolnp-2006 international search authority report.pdf 07 Oct 2011
9 02029-kolnp-2006 international publication.pdf 07 Oct 2011
10 02029-kolnp-2006 form-5.pdf 07 Oct 2011
11 02029-kolnp-2006 form-3.pdf 07 Oct 2011
12 02029-kolnp-2006 form-1.pdf 07 Oct 2011
13 02029-kolnp-2006 drawings.pdf 07 Oct 2011
14 02029-kolnp-2006 description(complete).pdf 07 Oct 2011
15 02029-kolnp-2006 correspondence others.pdf 07 Oct 2011
16 02029-kolnp-2006 claims.pdf 07 Oct 2011
17 02029-kolnp-2006 assignment.pdf 07 Oct 2011
18 02029-kolnp-2006 abstract.pdf 07 Oct 2011
19 2029-KOLNP-2006-(18-03-2016)-ABANDONED-LETTER.pdf 18 Mar 2016